Viral Vector & Plasmid DNA Manufacturing Market to Grow at 14.2% CAGR, Fueled by Gene Therapy Pipeline Expansion | Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech

Viral Vector and Plasmid DNA Manufacturing Market size was valued USD 2.85 billion in 2021 and is estimated to reach USD billion by 2031, growing at a CAGR of 14.2% during the forecast period 2024-2031.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/viral-vector-and-plasmid-dna-manufacturing-market?sg

Key Market Drivers:
Rising Demand for Gene and Cell Therapies:
The growing adoption of gene therapies for treating genetic disorders, cancer, and rare diseases has led to a surge in the demand for viral vectors and plasmid DNA, which serve as essential tools for gene delivery.

Increase in Clinical Trials and Research Programs:
A notable rise in clinical-stage gene therapy programs globally is intensifying the need for reliable and scalable manufacturing platforms for plasmids and vectors. This is especially true for Phase I and II trials.

Technological Advancements in Manufacturing:
Innovations in vector design, upstream and downstream processing, and automation are enhancing the yield, purity, and scalability of viral vector and plasmid DNA production. These advances are critical for meeting commercial-scale demand.

Supportive Regulatory Landscape:
Accelerated approval pathways, orphan drug designations, and funding grants in the U.S., Europe, and parts of Asia are encouraging biotech companies to invest in gene therapy, indirectly driving the manufacturing market.

Expansion of Contract Manufacturing Organizations (CMOs):
Due to the high cost and technical complexity of in-house production, many biopharma companies are outsourcing their vector and plasmid needs to CMOs. This outsourcing trend is driving capacity expansion across regions.

Emergence of Personalized Medicine:
The shift toward personalized therapeutics, particularly for oncology and inherited diseases, is driving innovation in vector and plasmid customization, increasing the demand for flexible and high-capacity manufacturing systems.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/viral-vector-and-plasmid-dna-manufacturing-market?sg

Market Segments:
• By Product Type (Plasmid DNA, Viral Vector, Non-Viral Vector)
• By Application (Cancer, Genetic Disorder, Infectious diseases, Other Diseases)
• By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Market Geographical Share
The global viral vector and plasmid DNA manufacturing market demonstrates strong growth potential across major regions, with North America leading the way. The United States holds a significant share, driven by the early adoption of advanced gene therapies, a high concentration of biotech firms, and strong government funding for genomic research. The presence of FDA-approved gene therapies has further spurred manufacturing demand in the region.

Europe follows closely, with Germany, the UK, and France emerging as major contributors. Supportive regulatory frameworks, expanding biopharmaceutical pipelines, and increasing clinical trial activity are pushing market growth across the continent. Furthermore, public-private collaborations have boosted infrastructure investments for cell and gene therapy manufacturing.

Asia-Pacific is experiencing the fastest growth, fueled by expanding R&D capabilities, lower manufacturing costs, and rising government support, particularly in countries like China, Japan, and South Korea. China, in particular, has made significant investments in cell and gene therapy hubs and has seen a surge in local biotech startups engaged in vector and plasmid production.

Market Key Players:
Key players are Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc.

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Product Launches & Pipeline Milestones:
• Boehringer Ingelheim's inhaled lentiviral therapy 'LENTICLAIR 1': In 2025, the first patient was dosed in a trial for cystic fibrosis using this inhaled lentiviral gene therapy, representing a novel delivery modality in respiratory gene therapies.

• FDA clearance of Kebilidi (eladocagene exuparvovec‐tneq): The first intracerebral AAV gene therapy in the U.S. was cleared in 2025 for treating AADC deficiency, ushering in a new era of direct-to-brain gene delivery.

2025 Key Developments:
Bharat Biotech and India's first dedicated viral vector facility in Hyderabad: In 2025, Bharat Biotech committed ~$75 million to build and operate this facility, signaling a major strategic investment in India's domestic capacity.

Platform Technology Designation by FDA: Sarepta's rAAVrh74 template received this designation in 2025, enabling streamlined regulatory submissions a move that may boost consolidation in vector platform licensing rather than direct M&A, but still strategic for market power.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.